Dabigatran Etexilate IR (WW) Pellets
Rraynex supplies Dabigatran Etexilate IR (WW) Pellets as immediate-release pellets in the Anticoagulant (Direct Thrombin Inhibitor) category, in strengths of 40%, 50%.
Product overview
Dabigatran etexilate is an oral direct thrombin inhibitor used for stroke prevention in atrial fibrillation and for venous thromboembolism.
Pharmaceutical pellets are small, free-flowing spherical units filled into capsules or compressed into MUPS tablets. Dividing a dose across many pellets gives more reproducible gastric transit and release than a single-unit tablet.
Formulation and release profile
Immediate-release (IR) pellets disintegrate and release the drug promptly, and are often combined with modified-release pellets in the same capsule.
Pharmaceutical applications
- Capsule filling of dabigatran etexilate ir (ww) pellets for anticoagulant products.
- Multiparticulate dosage forms where reproducible release matters.
- Formulation development, scale-up and commercial supply programmes.
Product specifications
- Product
- Dabigatran Etexilate IR (WW) Pellets
- Form
- immediate-release Pellets
- Therapeutic category
- Anticoagulant (Direct Thrombin Inhibitor)
- Available strengths
- 40%, 50%
- Grade
- IP / BP / USP / EP
- Pack size
- 25/50 kg
- Site certifications
- WHO-GMP, ISO 9001, ISO 14001
Detailed specifications, COA and technical documentation are shared on request.
Supply and enquiries
Rraynex supplies Dabigatran Etexilate IR (WW) Pellets to pharmaceutical manufacturers, formulation developers and CDMOs in 25/50 kg packs with batch traceability. Send your quantity, grade and documentation needs through the enquiry form and the commercial team will reply with specifications and a quotation. Rraynex is a B2B supplier and does not sell to consumers.
Send product enquiry Browse all pellets Manufacturing capabilities